213 related articles for article (PubMed ID: 21412012)
21. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
22. No association of the eNOS gene polymorphisms with survival in patients with colorectal cancer.
Kim YJ; Lee SJ; Kim JG; Sohn SK; Chae YS; Moon JH; Kang BW; Park JY; Park JS; Choi GS
Med Oncol; 2011 Dec; 28(4):1075-9. PubMed ID: 20706876
[TBL] [Abstract][Full Text] [Related]
23. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Pande M; Bondy ML; Do KA; Sahin AA; Ying J; Mills GB; Thompson PA; Brewster AM
Breast Cancer Res Treat; 2014 Sep; 147(2):381-7. PubMed ID: 25108739
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
25. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
Nan H; Han L; Ma J; Yang C; Su R; He J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
[TBL] [Abstract][Full Text] [Related]
26. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
27. MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through PTEN-Mediated PI3K/AKT Pathway.
Ke TW; Wei PL; Yeh KT; Chen WT; Cheng YW
Ann Surg Oncol; 2015 Aug; 22(8):2649-55. PubMed ID: 25515201
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
30. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.
Silvestris N; Tommasi S; Petriella D; Santini D; Fistola E; Russo A; Numico G; Tonini G; Maiello E; Colucci G
Oncology; 2009; 77 Suppl 1():69-74. PubMed ID: 20130434
[TBL] [Abstract][Full Text] [Related]
31. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.
Chen M; Gu J; Delclos GL; Killary AM; Fan Z; Hildebrandt MA; Chamberlain RM; Grossman HB; Dinney CP; Wu X
Carcinogenesis; 2010 Aug; 31(8):1387-91. PubMed ID: 20530239
[TBL] [Abstract][Full Text] [Related]
32. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
[TBL] [Abstract][Full Text] [Related]
33. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
[TBL] [Abstract][Full Text] [Related]
35. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Ekstrand AI; Jönsson M; Lindblom A; Borg A; Nilbert M
Fam Cancer; 2010 Jun; 9(2):125-9. PubMed ID: 19731079
[TBL] [Abstract][Full Text] [Related]
36. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
[TBL] [Abstract][Full Text] [Related]
37. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
38. Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology.
Zhang Y; Yao X; Jiang C; Yue J; Guan J; Cheng H; Hajirashid M; Wang Y; Fan L
Cancer Biomark; 2013; 13(4):299-305. PubMed ID: 24240591
[TBL] [Abstract][Full Text] [Related]
39. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
40. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
